A Study to Evaluate Whether Retinal Vasoreactivity is a Marker for Cerebrovascular Heath

Overview

About this study

The purpose of this study is to describe cerebral and retinal vasoreactivity in patients with cerebral small vessel disease (SVD) vs. healthy control, to describe temporal change of cerebral and retinal vasoreactivity, and to test the effectiveness of cilostazol in slowing the progression of white matter dementia (WMD).

 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years old.
  • Having cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), sporadic white matter dementia (WMD), lobar cerebral microbleeds (CMB) and age-matched healthy controls (e.g., patient’s spouse or unrelated friends without small vessel disease (SVD).
  • Subjects will be screened from the Mayo Clinic Florida Familial Cerebrovascular Disease Registry and prospectively from the Neurology Clinic (Cerebrovascular, Dementia, Continuity Clinic).

Exclusion Criteria:

  • Age < 18 years old.
  • Unable to follow commands.
  • Unable to tolerate MRI.
  • Pregnant or breast feeding.
  • Patients with sporadic WMD will undergo further exclusion before randomization to cilostazol  vs. placebo, including heart failure of any severity, atrial fibrillation, history of coronary artery disease, myocardial infarction, bleeding disorder, hypersensitivity to cilostazol, or has indication for antithrombotic. 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Michelle Lin, M.D., M.P.H.

Open for enrollment

Contact information:

Vickie Melton

(904) 953-8927

Melton.Vickie@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20509059

Mayo Clinic Footer